• Nicole A Braun, Lindsay J Celada, Jose D Herazo-Maya, Susamma Abraham, Guzel Shaginurova, Carla M Sevin, Jan Grutters, Daniel A Culver, Ryszard Dworski, James Sheller, Pierre P Massion, Vasiliy V Polosukhin, Joyce E Johnson, Naftali Kaminski, David S Wilkes, Kyra A Oswald-Richter, and Wonder P Drake.
• 1 Division of Infectious Diseases.
• Am. J. Respir. Crit. Care Med. 2014 Sep 1; 190 (5): 560-71.

RationaleEffective therapeutic interventions for chronic, idiopathic lung diseases remain elusive. Normalized T-cell function is an important contributor to spontaneous resolution of pulmonary sarcoidosis. Up-regulation of inhibitor receptors, such as programmed death-1 (PD-1) and its ligand, PD-L1, are important inhibitors of T-cell function.ObjectivesTo determine the effects of PD-1 pathway blockade on sarcoidosis CD4(+) T-cell proliferative capacity.MethodsGene expression profiles of sarcoidosis and healthy control peripheral blood mononuclear cells were analyzed at baseline and follow-up. Flow cytometry was used to measure ex vivo expression of PD-1 and PD-L1 on systemic and bronchoalveolar lavage-derived cells of subjects with sarcoidosis and control subjects, as well as the effects of PD-1 pathway blockade on cellular proliferation after T-cell receptor stimulation. Immunohistochemistry analysis for PD-1/PD-L1 expression was conducted on sarcoidosis, malignant, and healthy control lung specimens.Measurements And Main ResultsMicroarray analysis demonstrates longitudinal increase in PDCD1 gene expression in sarcoidosis peripheral blood mononuclear cells. Immunohistochemistry analysis revealed increased PD-L1 expression within sarcoidosis granulomas and lung malignancy, but this was absent in healthy lungs. Increased numbers of sarcoidosis PD-1(+) CD4(+) T cells are present systemically, compared with healthy control subjects (P < 0.0001). Lymphocytes with reduced proliferative capacity exhibited increased proliferation with PD-1 pathway blockade. Longitudinal analysis of subjects with sarcoidosis revealed reduced PD-1(+) CD4(+) T cells with spontaneous clinical resolution but not with disease progression.ConclusionsAnalogous to the effects in other chronic lung diseases, these findings demonstrate that the PD-1 pathway is an important contributor to sarcoidosis CD4(+) T-cell proliferative capacity and clinical outcome. Blockade of the PD-1 pathway may be a viable therapeutic target to optimize clinical outcomes.

38 keywords...

hide…